MusclePharm is a fast-growing healthy lifestyle company that develops and manufactures sports nutritional supplements. The company’s products are designed for people with active lifestyles who seek muscle building, weight maintenance, and general fitness through an internationally recognized daily nutritional supplement regimen.
The company today announced a strategic investment of $2 million into BioZone Pharmaceuticals Inc. (OTCQB: BZNE). Bio Zone is a developer, manufacturer, and marketer of over-the-counter drugs and preparations, cosmetics, and nutritional supplements for both retail chains and healthcare product marketing firms. It also owns novel drug delivery platforms, including its QuSome technology.
The investment was made in the form of a 10% secured convertible note due one year from the date of issuance. The note is convertible into common shares of BioZone Pharmaceuticals stock at a price of $0.20 per share. Additionally, MusclePharm received a 10-year warrant to purchase a further 10 million shares of BioZone common stock at an exercise price of $0.40 a share.
One of the reasons MusclePharm invested into BioZone Pharmaceuticals is its QuSome technology, which enhances the absorption of topical and other drugs. MusclePharm is studying the technology in connection with nutritional supplements to determine if the technology can enhance the absorption and speed delivery of its products.
In addition, MusclePharm announced it recently acquired 28 patents related to a proprietary transdermal drug delivery system that allows for precise control over both dosage and absorption rates. The system delivers drugs through the skin using low-level electrical energy that sends the drug directly to the bloodstream.
For more information about MusclePharm and its innovations for the sports nutrition market, please visit www.MusclePharm.com
Let us hear your thoughts below: